We are proud to present our 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014.
This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.
The agenda will give delegates an in-depth analysis on the strategies from bench to bedside to enhance drug development.
New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.
The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.
New sessions for 2014 will include:
Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction
Benefits of Attending
- Discuss and evaluate the latest new therapeutic mechanisms from bench to bedside with key insight from Merck, Spinifiex, Eli Lilly, AbbVie and UCB
- Hear key presentations from Mundipharma, Nektar and on advances to opioids and strategies to reduce abuse potential
- Explore the latest in the area of Neuropathic pain for 2014 with the latest case studies from Neuroscience Technologies and GW Pharmaceuticals
- Evaluate the translation gap with case studies from a pre-clinical and clinical perspective from Karolinska Institutet and OGB Consulting
Plus Two Interactive Half-Day Post-Conference Workshops
Wednesday 21st May 2014, Holiday Inn Regents Park Hotel, London, UK
- A: How Can Success in Analgesia be Improved?
Workshop Leaders: Steve Harrison, Vice President, Research Biology, Nektar Pharmaceuticals
Birgit Priest, Research Advisor, Eli Lilly
8.30am - 12.30pm
- B: Opportunities for Collaborative Pain Projects
Workshop Leader: Fiona Boissonade, Head of Neuroscience, University of Sheffield
1.30pm - 5.30pm
Speakers
- Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG
- Birgit Priest, Senior Scientist, Eli Lilly
- Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford
- Fiona Boissonade, Head of Neuroscience Research Group, The University Of Sheffield
- Howard Gutstein, Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center
- Jarkko Kalliomaki, Senior Consultant Physician, Stockholm Brain Institute
- Jordi Serra, CSO , Neuroscience Technologies Ltd
- Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research and Development LLC
- Misha Backonja, Medical Director, Neuroscience, PRA International
- Odd-Geir Berge, Independent Consultant, OGBConsulting
- Philip Kym, Associate Director II, Pain Discovery Research, Abbott Laboratories
- Praveen Anand, Professor, Clinical Neurology, Technology & Medicine
- Samer Eid, Neuroscience Scientific Knowlesge, Merck & Co.
- Stephen Wright, Director, R&D, G W Pharmaceuticals
- Steve Harrison, Vice President, Research Biology, Nektar Therapeutics
- Tom McCarthy, Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
- Zara Sands, Computational Medicinial Chemist, UCB
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK
Who Should Attend
Chief Executive Officer, Chief Scientific Officers, Managing Directors, Head of Department, Team Leaders, Principal Research Scientists in the following fields:
- Pain and Migraine
- Inflammation
- Chronic Pain
- Neuropathic Pain
- Analgesic pre-clinical development
- Anaesthesia and Pain Management
- CNS clinical trials
- Ion Channel Pharmacology
- Pharmacology Intelligence
Venue
Holiday Inn Kensington Forum
97 Cromwell Rd,
London, SW7 4DN
United Kingdom
